- Evelo Biosciences (NASDAQ:EVLO) announces that investigators at Rutgers University and Robert Wood Johnson University Hospital have submitted an IND to the FDA for a Phase 2 clinical trial evaluating lead candidate EDP1815 in newly diagnosed COVID-19 patients.
- The Rutgers Institute for Translational Medicine and Science and the New Jersey Alliance for Clinical and Translational Science will conduct the study.
- The company is evaluating EDP1815, an orally administered monoclonal strain of a gut bacterium called Prevotella histicola, in atopic dermatitis and psoriasis.
- Shares up 25% premarket on light volume.